Due to the new strains of COVID-19 and the lack of effective vaccines against them, investigations in the use of monoclonal antibodies in preventing the severe infection in comorbid patients with CKD 5D are highly relevant. The aim of our study was to evaluate the efficacy of monoclonal antibodies (tixagevimab AZD8895 and cilgavimab AZD1061) against different strains of SARS-Cov-2 for pre-exposure prophylaxis of severe COVID-19 infection in patients undergoing hemodialysis.
No takes yet. Share an insight, caveat, or question.
Shutov et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: